Regentis Biomaterials Ltd. RGNT
1.98
(0.06)
(2.94%)
as of 25 Sep
- Market cap
- $15.8M
- P/E
- —
Follow RGNT
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+1 more quarter Free account |
0.07 | 0.05 | 2.65 | 5.62 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
1,025.93% | 1,718.74% | 15.71% | 0.00% | |
Debt/Equity |
(0.12) | (0.18) | 0.25 | 0.00 | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | — | 0.00 | (6.60) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(0.64) | (0.34) | (1.37) | (2.84) | |
Working Capital |
(6.01) | (9.23) | 4.74 | 7.64 | |
Capital Expenditures |
0.00 | — | 0.00 | (0.03) | |
Net Current Asset Value |
(41.10) | (44.33) | 4.74 | 7.62 | |
| Other line items | |||||
Quick Ratio |
0.04 | 0.02 | 2.57 | 5.42 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Average Payables |
— | — | — | 0.27 | |
Average Assets |
— | — | — | 4.86 | |
Average Common Equity |
— | — | — | (19.11) | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates